Add Post-Exposure Prophylaxis to Regen-COV Protocols
You'll hear buzz about using casirivimab/imdevimab (Regen-COV) to PREVENT COVID-19...especially as cases continue to rise.
You already use this monoclonal antibody combo to TREAT mild to moderate COVID-19 in outpatients age 12 or older at high risk of severe illness.
Many patients are considered at high risk, such as those with diabetes...age 65 or older...or even with a BMI over 25.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive